Therefore, 2026 is a transition year, while broader Medicare Part D access for weight-loss GLP-1s is scheduled to expand through CMS models beginning in 2026 and 2027
Who should avoid Semaglutide Semaglutide is contraindicated for individuals with a history of thyroid cancer, multiple endocrine neoplasia syndrome, thyroid tumors, a personal or family history of endocrine disorders, or kidney disease, as well as those who are pregnant
The absence of safety data in these populations should inform clinical decision-making and prescribing practices
Photo Credit: Baldwin Publishing Staff Photographer 30 mins With a combination of black beans, quinoa, and chopped walnuts, these hearty, plant-based burgers provide a good mix of protein, fiber, and healthy fat
A consideration of its nature and current implications
Dose-Related Gastrointestinal events were reported more often in higher-dose research groups